drugset / Trial / NCT01188057
A Relative Bioavailability Study of 2 mg Alprazolam OD Tablets Under Non-Fasting Conditions
RandomizedCrossoverOpen-label
Summary
This study compared the relative bioavailability (rate and extent ofbsorption) of Alprazolam Orally Disintegrating Tablets, 2.0 mg by Purepac Pharmaceutical Co. with that of Niravam' 2 mg Orally Disintegrating Tablets manufactured for Schwarz Pharma, Inc. (by Cima Labs Inc.®)following a single, oral dose (I x 2 mg disintegrating tablet) in healthy adult volunteers administered under non-fasting conditions.
Timeline
- Start
- 2006-07
- Primary completion
- 2006-08
- Completion
- 2006-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Alprazolam | Small molecule | 2 mg | Oral |
Indications
No indication recorded.